Do analysts recommend DOMH or CDXS?

Codexis has a consensus target price of $5.00, indicating a potential upside of 240.14%. Given Codexis' stronger consensus rating and higher possible upside, analysts plainly believe Codexis is more favorable than Dominari. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dominari 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Codexis 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings & valuation, DOMH or CDXS?

Dominari has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dominari $123.10M 0.45 -$22.43M -$4.03 N/A Codexis $70.39M 1.90 -$43.97M -$0.37 N/A

Is DOMH or CDXS more profitable?

Dominari has a net margin of -31.37% compared to Codexis' net margin of -40.97%. Codexis' return on equity of -68.09% beat Dominari's return on equity. Company Net Margins Return on Equity Return on Assets Dominari -31.37% -206.20% -155.26% Codexis -40.97% -68.09% -23.72%

Does the media refer more to DOMH or CDXS?

In the previous week, Dominari had 2 more articles in the media than Codexis. MarketBeat recorded 4 mentions for Dominari and 2 mentions for Codexis. Dominari's average media sentiment score of 0.19 beat Codexis' score of 0.00 indicating that Dominari is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dominari 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Codexis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend FBIO or DOMH?

Fortress Biotech currently has a consensus price target of $17.00, indicating a potential upside of 536.70%. Given Fortress Biotech's stronger consensus rating and higher probable upside, equities analysts plainly believe Fortress Biotech is more favorable than Dominari. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fortress Biotech 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Dominari 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is FBIO or DOMH more profitable?

Fortress Biotech has a net margin of 193.12% compared to Dominari's net margin of -31.37%. Fortress Biotech's return on equity of 109.66% beat Dominari's return on equity. Company Net Margins Return on Equity Return on Assets Fortress Biotech 193.12% 109.66% 45.56% Dominari -31.37% -206.20% -155.26%

Does the media prefer FBIO or DOMH?

In the previous week, Fortress Biotech and Fortress Biotech both had 4 articles in the media. Dominari's average media sentiment score of 0.19 beat Fortress Biotech's score of 0.00 indicating that Dominari is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dominari 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate SGMO or DOMH?

Sangamo Therapeutics currently has a consensus target price of $5.50, indicating a potential upside of 7,332.43%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Sangamo Therapeutics is more favorable than Dominari. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sangamo Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75 Dominari 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SGMO or DOMH more profitable?

Dominari has a net margin of -31.37% compared to Sangamo Therapeutics' net margin of -310.81%. Dominari's return on equity of -206.20% beat Sangamo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sangamo Therapeutics -310.81% -2,662.06% -132.12% Dominari -31.37% -206.20% -155.26%

Do analysts rate CRIS or DOMH?

Curis presently has a consensus price target of $43.00, indicating a potential upside of 969.65%. Given Curis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Curis is more favorable than Dominari. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Dominari 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, CRIS or DOMH?

Curis has higher earnings, but lower revenue than Dominari. Dominari is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Curis $9.44M 0.83 -$7.58M -$23.80 N/A Dominari $123.10M 0.45 -$22.43M -$4.03 N/A

Is CRIS or DOMH more profitable?

Dominari has a net margin of -31.37% compared to Curis' net margin of -80.29%. Curis' return on equity of 0.00% beat Dominari's return on equity. Company Net Margins Return on Equity Return on Assets Curis -80.29% N/A -181.57% Dominari -31.37% -206.20% -155.26%

Does the media prefer CRIS or DOMH?

In the previous week, Dominari had 2 more articles in the media than Curis. MarketBeat recorded 4 mentions for Dominari and 2 mentions for Curis. Dominari's average media sentiment score of 0.19 beat Curis' score of 0.00 indicating that Dominari is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Curis 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dominari 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer BOLT or DOMH?

In the previous week, Dominari had 3 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 4 mentions for Dominari and 1 mentions for Bolt Biotherapeutics. Dominari's average media sentiment score of 0.19 beat Bolt Biotherapeutics' score of 0.00 indicating that Dominari is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bolt Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dominari 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Dominari (DOMH) Competitors

$2.45 -0.03 (-1.21%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$2.46 +0.01 (+0.41%)

As of 08/7/2026 07:34 PM Eastern

Compare

DOMH vs. CDXS, FBIO, SGMO, CRIS, and BOLT

Should you buy Dominari stock or one of its competitors? MarketBeat compares Dominari with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dominari include Codexis (CDXS), Fortress Biotech (FBIO), Sangamo Therapeutics (SGMO), Curis (CRIS), and Bolt Biotherapeutics (BOLT).

How does Dominari compare to Codexis?

Dominari (NASDAQ:DOMH) and Codexis (NASDAQ:CDXS) are related small-cap companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

Dominari has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market. Comparatively, Codexis has a beta of 2.54, indicating that its share price is 154% more volatile than the broader market.

In the previous week, Dominari had 2 more articles in the media than Codexis. MarketBeat recorded 4 mentions for Dominari and 2 mentions for Codexis. Dominari's average media sentiment score of 0.19 beat Codexis' score of 0.00 indicating that Dominari is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dominari	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Codexis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

42.5% of Dominari shares are owned by institutional investors. Comparatively, 78.5% of Codexis shares are owned by institutional investors. 55.3% of Dominari shares are owned by insiders. Comparatively, 3.5% of Codexis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Dominari has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dominari	$123.10M	0.45	-$22.43M	-$4.03	N/A
Codexis	$70.39M	1.90	-$43.97M	-$0.37	N/A

Dominari has a net margin of -31.37% compared to Codexis' net margin of -40.97%. Codexis' return on equity of -68.09% beat Dominari's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dominari	-31.37%	-206.20%	-155.26%
Codexis	-40.97%	-68.09%	-23.72%

Codexis has a consensus target price of $5.00, indicating a potential upside of 240.14%. Given Codexis' stronger consensus rating and higher possible upside, analysts plainly believe Codexis is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dominari	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Codexis	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Codexis beats Dominari on 9 of the 16 factors compared between the two stocks.

How does Dominari compare to Fortress Biotech?

Fortress Biotech (NASDAQ:FBIO) and Dominari (NASDAQ:DOMH) are related small-cap companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

Fortress Biotech has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market. Comparatively, Dominari has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

In the previous week, Fortress Biotech and Fortress Biotech both had 4 articles in the media. Dominari's average media sentiment score of 0.19 beat Fortress Biotech's score of 0.00 indicating that Dominari is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dominari	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

96.5% of Fortress Biotech shares are owned by institutional investors. Comparatively, 42.5% of Dominari shares are owned by institutional investors. 28.5% of Fortress Biotech shares are owned by insiders. Comparatively, 55.3% of Dominari shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Fortress Biotech currently has a consensus price target of $17.00, indicating a potential upside of 536.70%. Given Fortress Biotech's stronger consensus rating and higher probable upside, equities analysts plainly believe Fortress Biotech is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Dominari	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Fortress Biotech has higher earnings, but lower revenue than Dominari. Dominari is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.40	$6.82M	$3.17	0.84
Dominari	$123.10M	0.45	-$22.43M	-$4.03	N/A

Fortress Biotech has a net margin of 193.12% compared to Dominari's net margin of -31.37%. Fortress Biotech's return on equity of 109.66% beat Dominari's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	193.12%	109.66%	45.56%
Dominari	-31.37%	-206.20%	-155.26%

Summary

Fortress Biotech beats Dominari on 12 of the 15 factors compared between the two stocks.

How does Dominari compare to Sangamo Therapeutics?

Sangamo Therapeutics (NASDAQ:SGMO) and Dominari (NASDAQ:DOMH) are related small-cap companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Sangamo Therapeutics has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market. Comparatively, Dominari has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 42.5% of Dominari shares are held by institutional investors. 4.1% of Sangamo Therapeutics shares are held by company insiders. Comparatively, 55.3% of Dominari shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Dominari has higher revenue and earnings than Sangamo Therapeutics. Dominari is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A
Dominari	$123.10M	0.45	-$22.43M	-$4.03	N/A

Dominari has a net margin of -31.37% compared to Sangamo Therapeutics' net margin of -310.81%. Dominari's return on equity of -206.20% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
Dominari	-31.37%	-206.20%	-155.26%

Sangamo Therapeutics currently has a consensus target price of $5.50, indicating a potential upside of 7,332.43%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Sangamo Therapeutics is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Dominari	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Dominari had 4 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 4 mentions for Dominari and 0 mentions for Sangamo Therapeutics. Dominari's average media sentiment score of 0.19 beat Sangamo Therapeutics' score of 0.00 indicating that Dominari is being referred to more favorably in the news media.

Company	Overall Sentiment
Sangamo Therapeutics	Neutral
Dominari	Neutral

Summary

Sangamo Therapeutics beats Dominari on 9 of the 16 factors compared between the two stocks.

How does Dominari compare to Curis?

Curis (NASDAQ:CRIS) and Dominari (NASDAQ:DOMH) are related small-cap companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Curis has a beta of 3.13, meaning that its stock price is 213% more volatile than the broader market. Comparatively, Dominari has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

Dominari has a net margin of -31.37% compared to Curis' net margin of -80.29%. Curis' return on equity of 0.00% beat Dominari's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curis	-80.29%	N/A	-181.57%
Dominari	-31.37%	-206.20%	-155.26%

In the previous week, Dominari had 2 more articles in the media than Curis. MarketBeat recorded 4 mentions for Dominari and 2 mentions for Curis. Dominari's average media sentiment score of 0.19 beat Curis' score of 0.00 indicating that Dominari is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Curis	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dominari	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

30.0% of Curis shares are held by institutional investors. Comparatively, 42.5% of Dominari shares are held by institutional investors. 5.8% of Curis shares are held by insiders. Comparatively, 55.3% of Dominari shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Curis presently has a consensus price target of $43.00, indicating a potential upside of 969.65%. Given Curis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Curis is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dominari	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Curis has higher earnings, but lower revenue than Dominari. Dominari is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curis	$9.44M	0.83	-$7.58M	-$23.80	N/A
Dominari	$123.10M	0.45	-$22.43M	-$4.03	N/A

Summary

Curis and Dominari tied by winning 8 of the 16 factors compared between the two stocks.

How does Dominari compare to Bolt Biotherapeutics?

Bolt Biotherapeutics (NASDAQ:BOLT) and Dominari (NASDAQ:DOMH) are related small-cap companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Bolt Biotherapeutics has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, Dominari has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

Dominari has a net margin of -31.37% compared to Bolt Biotherapeutics' net margin of -455.15%. Bolt Biotherapeutics' return on equity of -100.89% beat Dominari's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bolt Biotherapeutics	-455.15%	-100.89%	-48.23%
Dominari	-31.37%	-206.20%	-155.26%

86.7% of Bolt Biotherapeutics shares are held by institutional investors. Comparatively, 42.5% of Dominari shares are held by institutional investors. 9.4% of Bolt Biotherapeutics shares are held by company insiders. Comparatively, 55.3% of Dominari shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Bolt Biotherapeutics currently has a consensus target price of $34.67, indicating a potential upside of 755.97%. Given Bolt Biotherapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Bolt Biotherapeutics is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Dominari	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Dominari had 3 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 4 mentions for Dominari and 1 mentions for Bolt Biotherapeutics. Dominari's average media sentiment score of 0.19 beat Bolt Biotherapeutics' score of 0.00 indicating that Dominari is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bolt Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dominari	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dominari has higher revenue and earnings than Bolt Biotherapeutics. Dominari is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bolt Biotherapeutics	$7.70M	1.01	-$33.38M	-$16.33	N/A
Dominari	$123.10M	0.45	-$22.43M	-$4.03	N/A

Summary

Bolt Biotherapeutics beats Dominari on 9 of the 16 factors compared between the two stocks.

Get Dominari News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DOMH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DOMH vs. The Competition

Export

Metric	Dominari	Capital Markets Industry	Finance Sector	NASDAQ Exchange
Market Cap	$55.40M	$5.58B	$14.06B	$13.02B
Dividend Yield	N/A	7.40%	5.89%	10.20%
P/E Ratio	-0.61	38.15	29.19	25.17
Price / Sales	0.45	1,236.38	507.97	88.07
Price / Cash	N/A	48.26	39.65	50.72
Price / Book	0.57	3.72	3.71	6.22
Net Income	-$22.43M	$417.17M	$1.31B	$342.66M
7 Day Performance	-3.54%	1.80%	1.43%	4.41%
1 Month Performance	-14.04%	0.77%	1.79%	-0.28%
1 Year Performance	-57.24%	6.94%	13.04%	22.60%

Dominari Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DOMH Dominari	0.238 of 5 stars	$2.45 -1.2%	N/A	-57.3%	$55.40M	$123.10M	N/A	4	Gap Up
CDXS Codexis	1.9007 of 5 stars	$1.50 -3.2%	$5.00 +233.3%	-47.1%	$140.89M	$70.39M	N/A	250	Upcoming Earnings Gap Down
FBIO Fortress Biotech	2.1849 of 5 stars	$3.39 +3.7%	$17.00 +401.5%	+44.3%	$108.63M	$63.26M	1.07	170	News Coverage Upcoming Earnings
SGMO Sangamo Therapeutics	1.0379 of 5 stars	$0.07 flat	$5.50 +7,332.4%	N/A	$30.66M	$39.55M	N/A	480
CRIS Curis	2.5337 of 5 stars	$4.83 +3.0%	$43.00 +790.3%	-88.3%	$9.14M	$9.44M	N/A	60	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DOMH) was last updated on 8/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dominari (DOMH) Competitors

DOMH vs. CDXS, FBIO, SGMO, CRIS, and BOLT

How does Dominari compare to Codexis?

Summary

How does Dominari compare to Fortress Biotech?

Summary

How does Dominari compare to Sangamo Therapeutics?

Summary

How does Dominari compare to Curis?

Summary

How does Dominari compare to Bolt Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DOMH vs. The Competition

Dominari Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dominari (DOMH) Competitors

DOMH vs. CDXS, FBIO, SGMO, CRIS, and BOLT

How does Dominari compare to Codexis?

Which has more volatility and risk, DOMH or CDXS?

Does the media refer more to DOMH or CDXS?

Do institutionals and insiders believe in DOMH or CDXS?

Which has higher earnings & valuation, DOMH or CDXS?

Is DOMH or CDXS more profitable?

Do analysts recommend DOMH or CDXS?

Summary

How does Dominari compare to Fortress Biotech?

Which has more risk & volatility, FBIO or DOMH?

Does the media prefer FBIO or DOMH?

Do insiders and institutionals have more ownership in FBIO or DOMH?

Do analysts recommend FBIO or DOMH?

Which has better earnings and valuation, FBIO or DOMH?

Is FBIO or DOMH more profitable?

Summary

How does Dominari compare to Sangamo Therapeutics?

Which has more risk & volatility, SGMO or DOMH?

Do insiders & institutionals have more ownership in SGMO or DOMH?

Which has better valuation & earnings, SGMO or DOMH?

Is SGMO or DOMH more profitable?

Do analysts rate SGMO or DOMH?

Does the media prefer SGMO or DOMH?

Summary

How does Dominari compare to Curis?

Which has more volatility & risk, CRIS or DOMH?

Is CRIS or DOMH more profitable?

Does the media prefer CRIS or DOMH?

Do insiders and institutionals have more ownership in CRIS or DOMH?

Do analysts rate CRIS or DOMH?

Which has higher earnings and valuation, CRIS or DOMH?

Summary

How does Dominari compare to Bolt Biotherapeutics?

Which has more risk and volatility, BOLT or DOMH?

Is BOLT or DOMH more profitable?

Do institutionals & insiders have more ownership in BOLT or DOMH?

Do analysts rate BOLT or DOMH?

Does the media prefer BOLT or DOMH?

Which has preferable valuation and earnings, BOLT or DOMH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DOMH vs. The Competition

Dominari Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools